ANI acquires generic Diflucan

ANI Pharmaceuticals is adding a Diflucan generic to its portfolio. The company has acquired fluconazole tablets, in dosage strengths of 50 mg, 100 mg, 150 mg, and 200 mg, from a private company for $3 million. 

"We are excited to add fluconazole tablets, currently manufactured at our site in Oakville, Canada, to our commercial generic portfolio," said Patrick Walsh, ANI's interim president and CEO. "With this acquisition, we further advance our strategy of expanding the ANI product portfolio via the Oakville plant.  By leveraging our commercial, manufacturing and packaging capabilities we expect to enhance the margin opportunity and competitive position of this product."

Fluconazole tablets is indicated for the treatment of vaginal candidiasis and oropharyngeal and esophageal candidiasis. It also is indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy.

The product had a market value of approximately $40 million, according to IQVIA.